F-18 fluciclovine (AxuminTM) PET/CT for prostate cancer biochemical recurrence - available at UPMC Shadyside since September 2017

UPMC Shadyside is the first site in Pittsburgh and southwestern Pennsylvania to offer a new F-18 Positron-Emission-Tomography/Computed-Tomography (PET/CT) scan for prostate cancer patients with biochemical recurrence. The novel PET agent F-18 fluciclovine (AxuminTM) was FDA approved in May 2016 and is useful for detecting low prostate-specific antigen (PSA) soft tissue and bone recurrence. This clinical service is the result of close collaboration between the Departments of Radiology and Radiation Oncology. Patients with F-18 PET/CT positive studies may be eligible for targeted radiotherapy: imaging data acquired can be directly retrieved and incorporated for radiation treatment planning.